文献速递心脏核医学

18F-Flurpiridaz正电子发射断层显像静息/负荷心肌灌注显像:小鼠可行性研究

Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice.
PubMed 文献 · J Nucl Cardiol · 2022-04-28

本研究在27只7-8月龄小鼠中采用18F-Flurpiridaz(0.6-3.0 MBq)行静息/负荷PET心肌灌注显像,以瑞加诺生(0.1 µg/g)诱导血管扩张负荷,评估示踪剂动力学与图像衍生心肌摄取。结果显示双组织室模型拟合最佳,心肌摄取百分比与VT相关性极好(20-40分钟平均摄取R2≥0.98),负荷/静息比值在K1、VT和%ID/g间几乎一致,提示基于图像衍生摄取的相对心肌灌注和冠脉血流储备评估在小鼠中可行。

要点

  • 18F-Flurpiridaz在小鼠静息/负荷PET-MPI中动力学以双组织室模型描述最佳。
  • 注射后20-40分钟平均心肌摄取与VT相关性极好(R2≥0.98)。
  • K1、VT和%ID/g的负荷/静息比值几乎一致,%ID/g可用于估算小鼠冠脉血流储备。

核心结论

  • 作者认为,基于图像衍生示踪剂摄取的相对心肌灌注和冠脉血流储备简化评估在小鼠中使用18F-Flurpiridaz是可行的,有助于在啮齿类动物中开展高通量机制性冠脉血流储备研究。

研究设计与样本

  • 研究在27只7-8月龄小鼠中行18F-Flurpiridaz(0.6-3.0 MBq)静息/负荷PET心肌灌注显像,使用瑞加诺生(0.1 µg/g)诱导血管扩张负荷。
  • 采用代谢物校正的动脉输入函数进行动力学建模,并通过在左心室心肌放置感兴趣体积评估不同时间间隔的图像衍生心肌18F-Flurpiridaz摄取。

主要发现

  • 示踪剂动力学以双组织室模型描述最佳,K1范围为6.7至20.0 mL·cm-3·min-1,心肌分布容积(VT)为34.6至83.6 mL·cm-3。
  • 在所有评估的时间间隔,静息和药物血管扩张后心肌18F-Flurpiridaz摄取(%ID/g)均与K1显著相关,但Spearman系数(rs)范围为0.478至0.681,R2值普遍较低。
  • 心肌18F-Flurpiridaz摄取与VT相关性极好,尤其在采用注射后20至40分钟的平均心肌摄取时R2≥0.98。
  • K1和VT对药物血管扩张诱导的敏感性相似,K1、VT和%ID/g 18F-Flurpiridaz的平均负荷/静息比值几乎一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myocardial perfusion imaging by positron emission tomography (PET-MPI) is the current gold standard for quantification of myocardial blood flow. 18F-flurpiridaz was recently introduced as a valid alternative to currently used PET-MPI probes. Nonetheless, optimum scan duration and time interval for image analysis are currently unknown. Further, it is unclear whether rest/stress PET-MPI with 18F-flurpiridaz is feasible in mice. METHODS: Rest/stress PET-MPI was performed with 18F-flurpiridaz (0.6-3.0 MBq) in 27 mice aged 7-8 months. Regadenoson (0.1 µg/g) was used for induction of vasodilator stress. Kinetic modeling was performed using a metabolite-corrected arterial input function. Image-derived myocardial 18F-flurpiridaz uptake was assessed for different time intervals by placing a volume of interest in the left ventricular myocardium. RESULTS: Tracer kinetics were best described by a two-tissue compartment model. K1 ranged from 6.7 to 20.0 mL·cm-3·min-1, while myocardial volumes of distribution (VT) were between 34.6 and 83.6 mL·cm-3. Of note, myocardial 18F-flurpiridaz uptake (%ID/g) was significantly correlated with K1 at rest and following pharmacological vasodilation for all time intervals assessed. However, while Spearman's coefficients (rs) ranged between 0.478 and 0.681, R2 values were generally low. In contrast, an excellent correlation of myocardial 18F-flurpiridaz uptake with VT was obtained, particularly when employing the averaged myocardial uptake from 20 to 40 min post tracer injection (R2 ≥ 0.98). Notably, K1 and VT were similarly sensitive to pharmacological vasodilation induction. Further, mean stress-to-rest ratios of K1, VT, and %ID/g 18F-flurpiridaz were virtually identical, suggesting that %ID/g 18F-flurpiridaz can be used to estimate coronary flow reserve (CFR) in mice. CONCLUSION: Our findings suggest that a simplified assessment of relative myocardial perfusion and CFR, based on image-derived tracer uptake, is feasible with 18F-flurpiridaz in mice, enabling high-throughput mechanistic CFR studies in rodents.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Bengs S, Warnock GI, Portmann A, et al. Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice. J Nucl Cardiol. 2022. PMID: 35484467. doi:10.1007/s12350-022-02968-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。